tubulin inhibitor 6

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

PKA inhibitor fragment (6-22) amide Acetate is a synthetic peptide which selectively inhibits PKA activity by binding to its substrate site (IC50 < 2 nM).

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.

Tubulin inhibitor 24 is a potent compound that inhibits tubulin polymerization.

Carbonic anhydrase inhibitor 6 is a potent human carbonic anhydrase (hCA) inhibitor that inhibits hCA IX, hCA II, hCA XII, and hCA I. It is used in the study of diseases caused by abnormalities in carbonic anhydrase.

Protein kinase inhibitor 6 (PKI 6) is a compound that acts as an inhibitor of protein kinases.

IK1 inhibitor PA-6 (PA-6) is a selective and potent inhibitor of IK1 (KIR2.x ion-channel-carried inward rectifier current) with an IC50 of 12-15 nM for human and mouse KIR2.x currents.

IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor-associated kinase 4 [IRAK-4, IC50: 160 nM].

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant, achieving 100% protein modification at 10 μM after 24 hours in vitro.

Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor with an IC50 of 1.09 μM. It inhibits cell migration and tube formation, exhibits anti-angiogenic properties, and effectively hinders tumor growth in HT29 xenograft Balb c nude mice [1].

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM, which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. As a microtubule destabilizer, Tubulin inhibitor 14 has potential tumor-selective, anti-angiogenic, and vascular-destructive properties [1].

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2/M phase.

Thrombin Inhibitor 6, with an IC 50 of 1 nM, acts as a potent anticoagulant by inhibiting thrombin.

Tubulin Inhibitor 28 (compound 2g), with an IC50 value of 1.2 μM, is a potent inhibitor of tubulin that exhibits significant anti-proliferative activity against MCF-7 cells [1].

RIP1 Kinase Inhibitor 6 is a potent and selective inhibitor of RIP1 kinase, demonstrating inhibitory activity with an IC50 of less than 100 nM in a human R1P1 kinase assay[1].

Mcl-1 inhibitor 6 is a potent, orally active chemical compound that selectively inhibits the myeloid cell leukemia 1 (Mcl-1) protein, with a high affinity (K d = 0.23 nM) and binding activity (K i = 0.02 μM). This compound exhibits exceptional selectivity over other members of the Bcl-2 family, including Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w (K d >10 μM). Notably, Mcl-1 inhibitor 6 demonstrates strong antitumor activity.

Glyoxalase I inhibitor 6 (Compound 9j) is an inhibitor of glyoxalase I (Glo-I) with an IC50 of 1.13 μM, exhibiting potential as a low-toxicity anticancer agent [1].

Tubulin Inhibitor 21 (compound 6f), a hybrid based on chalcone and melatonin, exhibits potent tubulin inhibition properties. It demonstrates significant cytotoxic activity against SW480 cells (IC 50 =0.26 μM) while showing lesser effects on nonmalignant cells [1].

Tubulin inhibitor 7 is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines (tubulin polymerization (IC50: 0.52 μM), K562 cell growth (IC50: 11 nM)).

Tubulin inhibitor 12 (Hit 9) is a recently developed compound with potent tubulin inhibitory effects (IC50 = 25.3 μM) and significant anti-tumor and anti-proliferative activities, making it a promising candidate for cancer treatment [1].

Tubulin inhibitor 26 (compound 3c) is an indazole derivative and a potent tubulin inhibitor with low nanomolar potency against HepG2, HCT116, SW620, HT29, and A549 cancer cell lines. It inhibits tumor cells in the G2 M phase, induces cell apoptosis, and suppresses tumor growth in vivo without affecting mice body weight [1].

KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.

Topoisomerase I inhibitor 6 (Compound 3) is a potent Topoisomerase I inhibitor that traps the DNA-Top1 cleavage complex and exhibits low cytotoxicity in non-cancerous cell lines, making it valuable for research.

SIRT5 Inhibitor 6 is a potent, selective, and substrate-competitive inhibitor of SIRT5 with an IC50 of 3.0 μM, demonstrating therapeutic potential for treating septic acute kidney injury (AKI) in vivo [1].

Chitin synthase inhibitor 6 (compound 9b) is a potent inhibitor of chitin synthase (CHS) with an IC50 of 0.21 mM, exhibiting broad-spectrum antifungal effects against drug-resistant fungi, and is useful for studying fungal infections.

GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β with an IC50 value of 24.4 μM, significantly enhancing hepatocyte glucose uptake (38%). This compound holds great potential for studying diseases such as diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1].

Tubulin inhibitor 23 is a potent tubulin inhibitor (IC50: 4.8 μM) that exhibits antiangiogenic effects in a dose-dependent manner and induces apoptosis. This compound shows potential for leukemia research.

ITK inhibitor 6 is a selective and potent ITK inhibitor that acts on ITK (IC50: 4 nM), BTK (IC50: 133 nM), JAK3 (IC50: 320 nM), EGFR (IC50: 2360 nM), LCK (IC50: 155 nM). ITK inhibitor 6 inhibited the phosphorylation of PLCγ1 and ERK1/2 and showed anti-proliferative effect.

Tubulin inhibitor 20 (compound 1) exhibits significant potential for cancer research as a potent tubulin inhibitor [1].

FGFR1 inhibitor-6 is a potent FGFR1 inhibitor (IC50: 16.31 nM) with cytotoxic activity, capable of blocking the cell cycle in pro-G1 and G2 M phases, and inducing apoptosis.

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC50 of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound exhibiting strong tubulin inhibitory activity, making it valuable for cancer research [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that disrupts tubulin assembly by binding at the colchicine site (IC50 = 1.2 μM), and exhibits antiproliferative effects on MCF-7 cells with an IC50 value of 7.5 μM. [1].

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM) that exhibits anticancer activities and induces cell apoptosis[1].

Tuberculosis inhibitor 6 (compound 2c), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, is highly active against Mycobacterium tuberculosis (MIC 90 of ≤1.66 μM) and Mycobacterium marinum (MIC 90 of 2.65 μM) [1].

Tubulin Inhibitor 34 (compound b5), a potent anticancer agent, inhibits tubulin polymerization and induces G2/M arrest and apoptosis. The compound demonstrates significant antivascular and antitumor activity [1].

URAT1 inhibitor 6 (Compound 1h), with an IC50 of 35 nM for hURAT1, demonstrates 200-fold and 8-fold greater potency compared to Lesinurad and Benzbromarone, respectively. This compound is utilized in the study of inflammation [1].